INTRODUCTION AND OBJECTIVES:
Chronic ischemia in the pelvis induces benign prostatic enlargement (BPE) in animal studies. However, whether local atherosclerosis induces BPE in humans has not yet been elucidated. To elucidate the mechanism of occurrence of BPH/BPE induced by the local atherosclerosis in humans, the association between local atherosclerosis and clinical background was investigated, and the molecular biological analyses was performed by using human surgical specimens.
METHODS: A total of 69 consecutive patients who underwent robot-assisted radical prostatectomy (RARP) participated in this prospective study. To evaluate actual local atherosclerosis, prostatic arteries were removed during RARP. Microscopic assessment of local atherosclerosis was classified as one of three degrees of narrowing (minimal, moderate, and severe) according to the degree of obstruction of the inner cavity of the prostatic artery. The expression of the several biomarkers related to the chronic ischemia and cell proliferation of the prostate was investigated by immunohistochemistry.
RESULTS: Local atherosclerosis of the prostatic artery was analyzed in 576 specimens (8.3AE5.0 specimens per patient). Local atherosclerosis was significantly more severe in patients who had a history of treatment for benign prostatic hyperplasia (P¼0.02). Prostate size was significantly lager in the severe local atherosclerosis group than in the minimal and moderate local atherosclerosis groups (P<0.001 and P¼0.03, respectively). There was a significantly negative correlation between prostate size and patency of the prostatic artery (r¼-0.30, P¼0.01). Multivariate analyses showed that prostate size was significantly correlated with local atherosclerosis (P¼0.04). In the immunohistochemical analyses, the positive expression rate of malondialdehyde (MDA), Hypoxia-inducible Factor (HIF)-1a, transforming growth factor (TGF)-b1and basic fibroblast growth factor(bFGF) in the prostate were significantly higher in the patients with local atherosclerosis than in the patients without local atherosclerosis (all P<0.01, respectively).
CONCLUSIONS: In human surgical specimens, local atherosclerosis of the prostatic artery induced prostatic enlargement. The increase in the obstruction in the prostatic artery was proportional to the increase of prostate size. Chronic ischemia due to local atherosclerosis led to the upregulation of oxidative stress and HIF-1a levels. Increase of TGF-b1and bFGF induced by oxidative stress and HIF-1a in the prostate might induce the enlargement of the prostate by the stromal proliferation, transdifferentiation, and extracellular matrix production.
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MP45-20 THE EFFECT ON BLOOD FLOW RATE OF PROSTATE IN DAILY ADMINISTRATION OF MIRODENAFIL 50MG FOR BENIGN PROSTATIC HYPERPLASIA PATIENTS: RANDOMIZED CONTROLLED STUDY
Kyu Shik Kim*, Jae Hoon Chung, Seoul, Korea, Republic of; Joon Hwa Noh, Jun Seok Kim, Gwangju, Korea, Republic of; Seung Wook Lee, Dong-Gi Lee, Seoul, Korea, Republic of INTRODUCTION AND OBJECTIVES: Erectile dysfunction (ED) and lower urinary tract symptom/ benign prostatic hyperplasia (LUTS/ BPH) has common pathophysiology. And phosphodiesterase type 5 inhibitor (PDE5-I) partially reverses the prostatic tissue contraction, and increases cyclic guanosine monophosphate to show antiproliferative effects in the prostatic smooth muscle cells and consequently, voiding symptoms were suggested to be improved. However, there was no definite mechanism of the effectiveness of PDE5-I on LUTS/BPH. Some previous study has reported the hypothesis which is PDE5-I improve the blood flow rate of prostate and it may improve the LUTS. In present study, by transrectal ultrasonography (TRUS), evaluated the change of blood flow rate of prostate after PDE5-I administration.
METHODS: Total 16 patients were included in this study. Among enrolled patients, 9 patients had once daily administrated mirodenafil 50mg for 1week, other 9 patients had administrated placebo daily. Peak systolic velocity (PSV) and end diastolic velocity (EDV) were estimated by TRUS at before medication and a day after last administration.
RESULTS: Baseline characteristics were no significant difference between two groups. In mirodenafil group showed 4.82 cm/sec increase of PSV and placebo group showed 0.29 cm/sec increase of PSV (p¼0.029). Moreover, mirodenafil group showed 0.38 cm/sec increase of EDV and placebo group showed 0.19 cm/sec decrease of EDV (p¼0.543).
CONCLUSIONS: Once daily administration of mirodenafil 50mg showed improvement of blood flow rate of prostate.
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